A Road Map of the Axial Spondyloarthritis Continuum

Schwartzman, Sergio; Ruderman, Eric

doi:10.1016/j.mayocp.2021.08.007

Cited by 13 publications

(1 citation statement)

References 114 publications

(167 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory disease characterised primarily by axial inflammation, in particular in the sacroiliac joints and in the spine. 1 Chronic back pain, stiffness and fatigue are key patient-reported symptoms; patients also often present with peripheral and extra-musculoskeletal manifestations. [2][3][4][5] There are two subtypes of axSpA: radiographic axSpA [r-axSpA, also known as ankylosing spondylitis (AS)] and non-radiographic axSpA (nr-axSpA).…”

Section: Introductionmentioning

confidence: 99%

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis

Rudwaleit,

Machado,

Taieb

et al. 2023

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: Patients with active axial spondyloarthritis (axSpA) exhibit more absences and lower levels of productivity in the workplace and household than the general population, which can improve upon treatment. Objectives: The objective of this study is to determine the long-term impact of achieving different levels of clinical response or disease activity on workplace and household productivity in patients with axSpA. Design: RAPID-axSpA (NCT01087762) was a 204-week phase III trial evaluating the safety and efficacy of certolizumab pegol (CZP) in adult patients with active axSpA. Methods: The impact of axSpA on workplace and household productivity was evaluated using the validated arthritis-specific Work Productivity Survey. Outcomes included the percentage of patients achieving Assessment of SpondyloArthritis International Society (ASAS) response and Ankylosing Spondylitis Disease Activity Score (ASDAS) thresholds. This post hoc study used a generalised estimating equations model to determine the association between the threshold of clinical response achieved and patient productivity. Results: Of 218 CZP-randomised patients, 65.1% completed week 204. At baseline, 72.0% were employed outside the home. Of the patients who were unemployed, 42.6% were unable to work due to arthritis. Achievement of higher treatment response thresholds, such as clinical remission, was associated with fewer days affected by workplace absenteeism (ASAS-partial remission: 4.0 days, ASAS40: 8.6 days, ASAS20 but not reaching ASAS40 response: 29.4 days, ASAS20 non-response: 69.2 days; ASDAS-inactive disease: 5.0 days, ASDAS-low disease activity: 15.6 days, ASDAS-high disease activity: 32.7 days, ASDAS-very high disease activity: 93.4 days). Similar associations were found for workplace presenteeism, and household absenteeism and presenteeism. Conclusions: Over 4 years, achievement of higher clinical response thresholds and lower levels of disease activity was associated with fewer cumulative days affected by absenteeism or presenteeism, with clinical remission associated with the greatest improvements in productivity. This highlights the importance of targeting these thresholds to limit the burden of axSpA on society and on patients’ daily lives.

show abstract

Section: Introductionmentioning

confidence: 99%

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis

Rudwaleit,

Machado,

Taieb

et al. 2023

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study

Deodhar,

Supronik,

Kivitz

et al. 2024

Arthritis & Rheumatology

View full text Add to dashboard Cite

ObjectiveTo assess the efficacy and safety of intravenous (IV) secukinumab for the treatment of adults with active axial spondyloarthritis (axSpA) in INVIGORATE‐1.MethodsINVIGORATE‐1 (NCT04156620) was a randomized, double‐blind, parallel‐group, phase III trial in patients with active axSpA (either radiographic or non‐radiographic). Patients were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every 4 weeks) or IV placebo for 16 weeks. After Week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg every 4 weeks), while patients randomized to secukinumab continued treatment through Week 52. The primary endpoint was Assessment of SpondyloArthritis international Society (ASAS40) response at Week 16. Safety was evaluated through Week 60.ResultsAmong patients initially randomized to IV secukinumab (n = 264) or placebo (n = 262), 86.0% and 88.9% completed the entire 60‐week study period, respectively. A higher proportion of patients receiving secukinumab vs placebo met the primary endpoint (ASAS40 response) at Week 16 (40.9% vs 22.9%; P<.0001). By Week 24, patients who switched from placebo to secukinumab at Week 16 achieved ASAS40 response rates comparable to those in patients originally randomized to secukinumab. All secondary efficacy endpoints were met at Week 16, and responses were sustained through Week 52. No new or unexpected safety signals were observed with IV secukinumab.ConclusionIV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. The safety profile was consistent with that in previous reports on subcutaneous secukinumab.

show abstract

Effects of Exercise Therapy in Axial Spondyloarthritis: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Trials

Zhang,

Liang,

Tian

et al. 2024

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

A Road Map of the Axial Spondyloarthritis Continuum

Cited by 13 publications

References 114 publications

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study

Effects of Exercise Therapy in Axial Spondyloarthritis: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Trials

Contact Info

Product

Resources

About